Type 2 Diabetes Med Growth in Asia

Markets Insider predicts in a recent Press Release that the "Market for type 2 diabetes mellitus (T2DM) [in South-East Asia] is expected to grow from $1.92 billion in 2016 to $2.96 billion in 2023, at a compound annual growth rate (CAGR) of 6.3%."

The Release names Invokana as one of the top-selling drugs that is expected to remain dominant, but does not discuss the increased risks with Invokana of foot and leg amputations, kidney failure and DKA, diabetic ketoacidosis and how that risk would be managed in South East Asia. The Report is available here.

Search

Just added to your cart:
Qty:
Total:
Subtotal:
Excl. postage 
My Bag
Just added to your wishlist:
Excl. postage 
My Wishlist